Kalkine Media lists 3 US penny stocks that soared in 2022 - Kalkine Media

December 30, 2022 07:44 AM PST | By Mridul Gogoi
Follow us on Google News:

Highlights:

  • ADMA Biologics Inc’s Q3 2022 revenue was US$ 41.4 million.  
  • Trevi Therapeutics Inc. posted total assets of US$ 128.36 million in Q3 2022.
  • Voyager Therapeutics achieved a collaboration revenue of US$ 41.086 million in Q3 2022.

 

Penny stocks can be highly risky to invest in because the performance of the individual companies varies a lot. However, since they are cheaper, investors tend to get lured by them. One must look at market conditions and the company fundamentals before investing in penny stocks. Moreover, the market condition has also been volatile since the start, making it even riskier.

Here, we take a look at three penny stocks and their performances in recent quarters:

ADMA Biologics Inc (NASDAQ: ADMA)

ADMA Biologics is a biopharmaceutical company that manufactures, markets, and develops plasma-derived biologics used to treat infectious diseases.

The company posted a revenue of US$ 41.4 million in the third quarter of 2022, up 99 per cent from the same period in 2021. Its gross profit in the reported quarter was US$ 9.65 million compared to US$ 0.385 million in the year-ago quarter.

The company's net loss in Q3 2022 came down to US$ 14.899 million against a net loss of US$ 17.712 million in Q3 2021.

The ADMA stock surged over 151 per cent YTD.        

Trevi Therapeutics Inc. (NASDAQ: TRVI)

Trevi Therapeutics develops and sells/distributes nalbuphine ER to treat serious neurologically mediated conditions. The biopharmaceutical company has a price-to-book (P/B) ratio of 1.017.

The clinical-stage company said its R&D expenses for the third quarter of 2022 was US$ 5.8 million. It was higher than US$ 4.7 million in the corresponding quarter in the previous year. This increase was mainly due to its various startup activities for the scheduled trials.

At the end of the quarter that ended September 30, 2022, Trevi had total assets of US$ 128.36 million compared to US$ 38.47 million at the end of the quarter that ended December 31, 2021. The company reported a net loss of US$ 8.266 million in Q3 2022 compared to US$ 7.255 million in the year-ago quarter. The TRVI stock soared over 148.10 per cent year-to-date.

ADMA Biologics Inc gross profit and net loss Q3 2022 v Q3 2021Source: ©Kalkine Media®; © Canva via Canva.com

Voyager Therapeutics Inc. (NASDAQ: VYGR)

Gene therapy company Voyager Therapeutics develops life-changing treatments for patients with severe neurological diseases. 

In the third quarter of fiscal 2022, Voyager posted a collaboration revenue of US$ 41.086 million compared to just US$ 1.482 million in the same quarter in 2021. The company’s net income in Q3 2022 was US$ 17.62 million versus a loss of US$ 25.13 million in the corresponding quarter a year ago.

Notably, the diluted net income per share was US$ 0.45 in the third quarter of this year compared to loss of US$ 0.67 in Q3 2021. The VYGR stock climbed over 96.65 per cent YTD.

Bottom line:

Participants are always wary of losing their money in a volatile stock market. However, if you have a long-term strategy and a diversified portfolio, about it might help you adapt to the frequently changing market conditions. Just do your analysis thoroughly and then take any decisions to stay protected in a bearish market trend.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.



Top Listed Companies